1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
66EF6586B5E9E3F9000258520006F1F2E
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-Americas-MSL-Excellence-Optimizing-resources-for-field-medical-operations-in-the-Americas?opendocument
18
19opendocument
2044.210.149.218
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Medical Affairs » Field Medical Excellence

Americas MSL Excellence: Optimizing resources for field medical operations in the Americas

ID: 5603


Features:

14 Info Graphics

16 Data Graphics

250+ Metrics

4 Narratives


Pages/Slides: 35


Published: 2020


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Americas MSL Excellence: Optimizing resources for field medical operations in the Americas"

STUDY OVERVIEW

The country-specific dynamics of a market can play an outsized role in whether or not your products are embraced by thought leaders or shrugged off in favor of established competition. Are you coordinating and staffing your MSL function appropriately for each of your markets?

Best Practices, LLC conducted this Americas-focused study to help pharmaceutical leaders seeking reliable field medical resourcing metrics on current MSL deployment operations in the Americas that includes Brazil, Mexico and Canada. There is no U.S. data in this document.

The study provides Americas metrics on MSL staffing, travel and entertainment budget, and MSL utilization during the entire product lifecycle. Pharmaceutical leaders will be able to use the research results to see how their MSL resourcing strategies in the Americas stack up against industry averages and trends.

Critical MSL resourcing questions addressed in this study include:

  • Staffing levels
  • T&E spend levels
  • MSL utilization during pre-launch, launch, and post-launch

    KEY TOPICS
  • Executive Summary
  • Resourcing MSLs: Staffing, T&E budgets and launch support
KEY METRICS
  • Average number of brands (including both in-line and pre-launch products) supported by each MSL in each of the listed countries – All regions
  • Average number of brands (including both in-line and pre-launch products) supported by each MSL in each of the listed countries – Americas countries
  • Total number of MSLs staffed in each country; total number of MSLs supporting each therapeutic area – All regions
  • MSL staffing footprint in each of the listed Americas countries
  • Total number of MSLs staffed in each country per therapeutic area supported
  • Approximate annual total travel and entertainment (T&E) budget allocated to MSLs – All regions
  • Approximate annual total travel and entertainment (T&E) budget allocated to MSLs in each of the listed countries – Americas countries
  • Additional MSL staffing and T&E budget data from non-target Americas countries
  • Total number of staff allocated to each of the listed MSL management and support roles; Americas span of field control
  • Average percentage of “peak MSL team size” assigned to support a product at each phase of the typical product lifecycle – All regions
  • Average percentage of “peak MSL team size” assigned to support a product at each phase of the typical product lifecycle – Americas countries
  • Interview narrative around MSL knowledge during phase II
  • Effective timing in Europe to bring an MSL on board to support a product in each phase of the product lifecycle
  • Interview narrative around launch success for field medical teams
  • Effective timing to bring an MSL on board to support a product in each phase of the product lifecycle in each of the targeted Americas countries
SAMPLE KEY FINDINGS
  • T&E Budget: Average annual budgets are both ample in the large markets of Canada ($18,162) and Brazil ($15,875). One interviewed Global MA VP described a cost-efficient field approach of using contracted physicians to serve as de facto MSLs in Argentina and Brazil: “We tap ‘up and comers.’ they maintain their practices, but we train them, they elevate their profile in the region, we develop essentially our own KOLs, and don’t take on additional headcount.”


METHODOLOGY

Best Practices, LLC engaged 125 Global Medical Affairs and Field Medical Excellence leaders from more than 40 leading pharma and biotech companies in this research through a benchmarking survey. In-depth interviews were conducted with 8 benchmark partners to gain further insights.

Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Biotech; Manufacturing; Consumer Products; Medical Device; Chemical; Biopharmaceutical; Clinical Research; Laboratories


Companies Profiled:
Abbott; Alexion Pharmaceuticals; Allergopharma; Amgen; AstraZeneca; Bayer; Biogen; Bioventus; Boehringer Ingelheim; Celgene; Chiesi; Clovis Oncology; Dr Reddy's Laboratories; Eisai; Galderma; GE Healthcare; Gedeon Richter ; Gilead Sciences; Grifols; Ipsen; Janssen; Kiniksa Pharmaceuticals; Kyowa Kirin; Merck Serono; Merck; Novartis; Pfizer; Rakuten Medical; Roche; Sandoz; Sanofi; Lupin; Shire; Takeda Pharmaceuticals; Sunovion; UCB Pharma; Vertex Pharmaceuticals; Vifor Pharma; ViiV Healthcare

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.